Chimerix, Inc. (CMRX)
- Previous Close
0.9639 - Open
0.9740 - Bid 0.9624 x 100
- Ask 0.9955 x 100
- Day's Range
0.9519 - 0.9799 - 52 Week Range
0.8800 - 1.5700 - Volume
98,178 - Avg. Volume
308,771 - Market Cap (intraday)
86.654M - Beta (5Y Monthly) 1.12
- PE Ratio (TTM)
-- - EPS (TTM)
-0.9400 - Earnings Date Aug 1, 2024 - Aug 5, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chimerix, Inc., a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors. The company also develops ONC212, an imipridone agonist of the orphan G protein-coupled receptors (GPCR) tumor suppressor GPR132, as well as ClpP for oncology indications; and CMX521, a nucleoside analog antiviral drug candidate for the treatment of SARS-CoV-2. It has license agreement with SymBio Pharmaceuticals to develop and commercialize TEMBEXA for human diseases other than orthopoxviruses, including smallpox. Chimerix, Inc. was incorporated in 2000 and is headquartered in Durham, North Carolina.
www.chimerix.comRecent News: CMRX
Performance Overview: CMRX
Trailing total returns as of 5/31/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CMRX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CMRX
Valuation Measures
Market Cap
86.65M
Enterprise Value
-71.37M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
2.10k
Price/Book (mrq)
0.50
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-26.30%
Return on Equity (ttm)
-39.86%
Revenue (ttm)
41k
Net Income Avi to Common (ttm)
-82.59M
Diluted EPS (ttm)
-0.9400
Balance Sheet and Cash Flow
Total Cash (mrq)
159.03M
Total Debt/Equity (mrq)
0.96%
Levered Free Cash Flow (ttm)
-35.03M